programdemand

Fresh results from Richard Webby at St. Jude Children’s Enquiry Hospital and colleagues published in the ecumenical open-access medical newsletter PLoS Medicine imply that the rebutter might be yes.

The H5N1 avian flu virus is quite different from the seasonal H1N1 and H3N2 flu viruses most humans own been exposed to, which is why many scientists believe that H5N1 could start a new pandemic. (The H and N refer to two virus components, the proteins hemagglutinin and neuraminidase, each of which exists in several varieties identified by a number following the note.)

Webby and colleagues wondered whether immunity to the human sort 1 neuraminidase (huN1) in H1N1 influenza virus strains (and vaccines made to take care of against them) could provide protection against avian H5N1 influenza virus, which contains the closely related avian type 1 neuraminidase (avN1). In the chic study, they investigated this possibility in mice and in a small group of humans.

The researchers immunized mice with DNA that caused their cells to make the neuraminidase from an H1N1 virus found in Possibly manlike outbreaks. They then examined the immune response of the mice to this huN1 and to avN1 from an avian H5N1 virus isolated from a human firm (A/Vietnam/1203/04). Most of the mice responded to the DNA vaccine by making antibodies that recognized huN1; a few also made antibodies against avN1. (Antibodies are proteins circulating in the portion that recognize and penetrate to some specific part of a peculiar agent such as a virus.) All the vaccinated mice survived infection with a man-made flu virus containing huN1, and half also survived infection with low doses of A/Vietnam/1203/04 or of a man-made virus containing avN1.

The researchers then tested blood samples from 38 human volunteers for their ability to inactivate neuraminidase from an H1N1 virus and two H5N1 viruses. Most of the samples were active against the protein from the H1N1 virus; and 8 or 9 also restrained the protein from both H5N1 viruses.

The results need that a vaccine containing huN1 makes mice produce antibodies that partly protect them against avian H5N1 infection. In furthermore, the human data advocate that a proportion of people have low titer antibodies against H5N1 influenza because of prior divulging to H1N1 viruses or routine influenza vaccination.

As Laura Gillim-Ross and Kanta Subbarao (US National Institute of Allergy and Infectious Diseases) write in an accompanying Approach article, these results present a tantalizing suggestion but fall short of demonstrating that there is actual custody in humans against avian flu. More distant work is needed to investigate this important question, and Gillim-Ross and Subbarao about the challenges and opportunities in behalf of such experimentation.

—————————-
Article adapted by Medical Newscast Today from original press unshackle.
—————————-

Entire lot published by PLoS Medicine is Open Access: freely elbow for anyone to skim, download, redistribute and otherwise handle, as great as the authorship is properly attributed.

Both articles will also be part of a collection of articles published in PLoS Physic and other PLoS journals on many aspects of influenza biology and sway. The collection are lodge at http://collections.plos.org/plosmedicine/influenza-2007.php

Citation: Sandbulte MR, Jimenez GS, Present ACM, Smith LR, Treanor JJ, et al. (2007) Cross-reactive neuraminidase antibodies bear the expense partial sponsorship against H5N1 in mice and are present in unexposed humans. PLoS Med 4(2): e59.

SUIT SUM THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR COMMUNIQUE

FRIEND:

St. Jude Public Relations

Interdependent PLoS Cure-all Approach article:

Citation: Gillim-Ross L, Subbarao K (2007) Can immunity induced by the human infl uenza virus N1 neuraminidase get ready for some protection from avian infl uenza H5N1 viruses? PLoS Med 4(2): e91.

PLEASE ADD THE CONNECTOR TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT

Contact: Andrew Hyde

Public Library of Body of knowledge